Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults (CoronaVac3CL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04651790
Recruitment Status : Recruiting
First Posted : December 3, 2020
Last Update Posted : March 2, 2021
Sponsor:
Collaborators:
Ministry of Health, Chile
Sinovac Biotech Co., Ltd
Information provided by (Responsible Party):
Pontificia Universidad Catolica de Chile

Tracking Information
First Submitted Date  ICMJE November 20, 2020
First Posted Date  ICMJE December 3, 2020
Last Update Posted Date March 2, 2021
Actual Study Start Date  ICMJE November 27, 2020
Estimated Primary Completion Date January 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: February 8, 2021)
  • Frequency of solicited and unsolicited adverse events that occur during the period of one week after each dose of the vaccine in two vaccination schedules: 0,14 and 0,28 days stratified by age group (18-59 years, and 60 or more years). [ Time Frame: During the first 7 days after each dose of vaccine ]
    The frequency of solicited and unsolicited local and systemic adverse reactions will be registered. This will be measured during the first 7 days after each vaccination. These adverse reactions will be registered according to the age group in adults (18-59 years old) and the elderly (60 years of age or older).
  • Incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second dose of each vaccination schedule. [ Time Frame: Two weeks after second dose up to one year after first dose ]
    Vaccine efficacy to prevent virologically confirmed COVID-19 two weeks after the second dose of each vaccination schedule will be determined
Original Primary Outcome Measures  ICMJE
 (submitted: December 1, 2020)
  • Incidence of symptomatic cases of virologically confirmed COVID-19 two weeks after the second vaccination [ Time Frame: Two weeks after second dose up to one year after first dose ]
    Vaccine efficacy to prevent virologically confirmed COVID-19 two weeks after the second vaccination will be determined
  • Frequency of solicited and unsolicited local and systemic adverse reactions during the period of one week after vaccination according to age group in adult (18-59 years old) and elder (60 years of age or older) subjects. [ Time Frame: During the first 7 days after each dose of vaccine/placebo ]
    The frequency of solicited and unsolicited local and systemic adverse reactions will be registered. This will be measured during the first 7 days after each vaccination. These adverse reactions will be registered according to the age group in adult (18-59 years old) and elder (60 years of age or older) subjects.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: February 8, 2021)
  • Incidence of hospitalized cases of COVID-19 two weeks after the second vaccination of two vaccination schedules [ Time Frame: Since two weeks after the second dose of two vaccination schedules and up 12 month after first dose ]
    The incidence of hospitalized cases of COVID-19 two weeks after the second vaccination of two vaccination schedules will be determined.
  • Incidence of severe cases or deaths of COVID-19 virologically confirmed two weeks after the second vaccination of two vaccination schedules [ Time Frame: Since two weeks after the second dose up 12 month after first dose ]
    The incidence of severe cases of COVID-19 and deaths, confirmed through PCR, two weeks after the second vaccination of two vaccination schedules, will be determined.
  • Incidence of adverse reactions to the vaccine, local and systemic, solicited and unsolicited, within the period of four weeks after each vaccination of two vaccination schedules, according to the age, adults (18-59 years old) and elder (>60 years) [ Time Frame: Four weeks after each dose of vaccine in two vaccination schedules ]
    The incidence of adverse reactions to the vaccine, both local and systemic, solicited and unsolicited will be determined. These adverse reactions will be measured within the period of four weeks after each dose of vaccination of two vaccination schedules. These adverse reactions will be registered according to the age group in adult (18-59 years old) and elder (60 years of age or older) subjects
  • Frequency of severe COVID-19 cases in participants who received at least one dose of vaccine in two vaccination schedules [ Time Frame: Since first dose up to 12 month after ]
    The frequency of severe COVID-19 cases in participants who received at least one dose of vaccine in two vaccination schedules will be determined.
  • Incidence of serious adverse events (SAE) and adverse events in participants who have received at least one dose of the vaccine, in two vaccination schedules [ Time Frame: Since first dose up to 12 month after ]
    The occurrence of serious adverse events (SAE) and adverse events of special interest in participants who have received at least one dose of the vaccine in two vaccination schedules, will be determined
  • Percentage of participants that show a significant increase in SARS-CoV-2 specific T cells after vaccination, in two vaccination schedules, determined by flow Cytometry and ELISPOT [ Time Frame: Since first dose up to 4 weeks after second dose ]
    The cellular immune response in a subgroup of participants, before and two and four weeks after the administration of each dose of the vaccine, in two vaccination schedules will be evaluated
  • Percentage of participants with a significant increase of anti-SARS-CoV-2 antibodies, determined by ELISA [ Time Frame: Since first dose up to 2 weeks after second dose ]
    The presence of anti-SARS-CoV-2 antibodies in a subgroup of participants, before and two weeks after the administration of each dose of the vaccine, in two vaccination schedules, will be evaluated.
  • Percentage of participants that show a significant increase in SARS-CoV-2 specific T cells after vaccination, determined by flow Cytometry and ELISPOT [ Time Frame: Since first dose up to 4 weeks after second dose ]
    The cellular immune response in a subgroup of participants, before and two and four weeks after the administration of each dose of the vaccine, will be evaluated.
Original Secondary Outcome Measures  ICMJE
 (submitted: December 1, 2020)
  • Incidence of cases of virologically confirmed COVID-19 after administration of at least one dose of vaccine/placebo [ Time Frame: Since first dose and up to 12 months after ]
    The incidence of cases confirmed through PCR for COVID-19 after administration of at least one dose of vaccine/placebo will be determined.
  • Incidence of severe cases of COVID-19 virologically confirmed two weeks after the second vaccination [ Time Frame: Since two weeks after the second dose up 12 month after first dose ]
    The incidence of severe cases of COVID-19, confirmed through PCR, two weeks after the second vaccination, will be determined.
  • Incidence of hospitalized cases of COVID-19 two weeks after the second vaccination [ Time Frame: Since two weeks after the second dose and up 12 month after first dose ]
    The incidence of hospitalized cases of COVID-19 two weeks after the second vaccination will be determined.
  • Incidence of deaths due to COVID-19 two weeks after the second vaccination [ Time Frame: Since two weeks after the second dose up 12 month after first dose ]
    The incidence of deaths due to COVID-19 two weeks after the second vaccination will be determined.
  • Incidence of adverse reactions to the vaccine, local and systemic, solicited and unsolicited, within the period of four weeks after each dose of vaccination, according to the age group, adults (18-59 years old) and elder (60 years or older) subjects. [ Time Frame: Four weeks after each dose of vaccine/placebo ]
    The incidence of adverse reactions to the vaccine, both local and systemic, solicited and unsolicited will be determined. These adverse reactions will be measured within the period of four weeks after each dose of vaccination. These adverse reactions will be registered according to the age group in adult (18-59 years old) and elder (60 years of age or older) subjects.
  • Frequency of severe COVID-19 cases in participants who received at least one dose of vaccine/placebo [ Time Frame: Since first dose up to 12 month after ]
    The frequency of severe COVID-19 cases in participants who received at least one dose of vaccine/placebo will be determined.
  • Incidence of serious adverse events (SAE) and adverse events in participants who have received at least one dose of the vaccine [ Time Frame: Since first dose up to 12 month after ]
    The occurrence of serious adverse events (SAE) and adverse events of special interest in participants who have received at least one dose of the vaccine, will be determined.
  • Percentage of participants that show a significant increase in SARS-CoV-2 specific T cells after vaccination, determined by flow Cytometry and ELISPOT [ Time Frame: Since first dose up to 4 weeks after second dose ]
    The cellular immune response in a subgroup of participants, before and two and four weeks after the administration of each dose of the vaccine, will be evaluated.
  • Percentage of participants with a significant increase of anti-SARS-CoV-2 antibodies, determined by ELISA [ Time Frame: Since first dose up to 2 weeks after second dose ]
    The presence of anti-SARS-CoV-2 antibodies in a subgroup of participants, before and two weeks after the administration of each dose of the vaccine, will be evaluated.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults
Official Title  ICMJE Multicenter, Phase 3, Randomized Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against SARS-CoV-2 Infection in Adults.
Brief Summary The study will evaluate the efficacy, safety, and immunogenicity of two vaccination schedules of an inactivated vaccine against SARS-CoV-2 infection in adults. Two doses of the vaccine will be administered in a 0,14 and a 0,28-day schedule. Follow-up of safety and efficacy will be assessed for 12 months after the first dose. Immunogenicity will be studied in a subgroup of participants.
Detailed Description This study will evaluate the efficacy, safety, and immunogenicity of two vaccination schedules of an inactivated vaccine against SARS-CoV-2 infection in adults. This study will be performed in 8 centers. Two schedules will be compared: 0,14 and 0,28-day, at a 1:1 rate. 40% of participants will be 60 or more years-old. Follow-up of safety and efficacy will be assessed for 12 months after administering the first dose. The collection of the data will be through an electronic Case Report Form. Immunogenicity will be studied in a subgroup of participants. Initially, 2,300 volunteers will be recruited.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE
  • Covid19
  • Vaccines
Intervention  ICMJE Biological: SARS-CoV-2 inactivated vaccine
The vaccine contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate and sodium chloride.The final product will be supplied in a pre-filled syringe containing 0.5 ml of solution for injection that corresponds to a dose of the vaccine.
Other Name: Coronavac
Study Arms  ICMJE
  • Active Comparator: Vaccine 0-14
    Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 14
    Intervention: Biological: SARS-CoV-2 inactivated vaccine
  • Experimental: Vaccine 0-28
    Inactivated vaccine against SARS-CoV-2 2 doses on day 0 and 28
    Intervention: Biological: SARS-CoV-2 inactivated vaccine
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 1, 2020)
2300
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE March 2022
Estimated Primary Completion Date January 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adults over 18 years of age.
  • Demonstrate the capacity to understand and sign the Informed Consent document.
  • Agree to comply with the study procedures and visits.

Exclusion Criteria:

  • History of confirmed symptomatic SARS CoV-2 infection.
  • Pregnant (confirmed by positive urine pregnancy test) or breastfeeding females, and/or expressing intention to have sexual practices with reproductive potential without using contraceptive methods in the three months following vaccination.
  • History of an allergic reaction to the vaccine or components of the study vaccine or placebo.
  • Evidence of uncontrolled neurological, cardiac, pulmonary, hepatic, or renal disease, according to anamnesis or physical examination; Significant changes in treatment or hospitalizations due to worsening of the condition in the last three months are indicators of uncontrolled disease.
  • Diseases that impair the immune system including neoplasms (except basal cell carcinoma), congenital or acquired immunodeficiencies, and uncontrolled autoimmune diseases not controlled according to anamnesis or physical examination.
  • Behavioral, cognitive, or psychiatric illness that, in the opinion of the principal investigator or his medical representative, affects the participant's ability to understand and collaborate with the requirements of the study protocol.
  • Use of immunosuppressive therapies six months before inclusion in the study or its scheduled use within two years of inclusion. Immunosuppressive therapies will be considered: antineoplastic chemotherapy, radiation therapy, immunosuppressants to induce tolerance to transplants, among others.
  • Have received an immunosuppressive dose of corticosteroids in the last three months before inclusion in the study or scheduled administration of an immunosuppressive dose of corticosteroids for the three months following inclusion in the study. The dose of corticosteroids considered immunosuppressive is equivalent to prednisone at a dose of 20 mg/day for adults for more than a week. The continuous use of topical or nasal corticosteroids is not considered immunosuppressive.
  • History of asplenia, either anatomic or functional.
  • History of bleeding disorders, as deficiency of clotting factors, coagulopathy, platelet dysfunction, or previous history of bleeding or significant bruising after IM injection or venipuncture.
  • Any alcohol or drug abuse in the last 12 months before inclusion in the study that has caused medical, professional, or family problems, as indicated by clinical history.
  • Have received blood products (transfusions or immunoglobulins) in the last three months before inclusion in the study.
  • Have received any vaccine with a live attenuated virus in the last 28 days or inactivated vaccine in the last 14 days before their inclusion in the study, or have immunization scheduled for the first 28 days after their inclusion in the study.
  • Participation in another clinical trial with product administration under investigation during the six months before its inclusion in the study or scheduled participation in another clinical trial in the two years following inclusion.
  • Previous participation in a COVID-19 vaccine evaluation study or previous exposure to a COVID-19 vaccine.
  • Fever (>37.8°C) within 72 hours before vaccination.
  • Any other condition that, in the opinion of the principal investigator or his medical representative, could jeopardize the safety or rights of a potential participant or that would prevent him from complying with this protocol.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE
Contact: Katia Abarca, MD +56996797787 katia@med.puc.cl
Contact: Carolina Iturriaga, Nurse +56991292169 citurriaga@med.puc.cl
Listed Location Countries  ICMJE Chile
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04651790
Other Study ID Numbers  ICMJE 200708006
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Pontificia Universidad Catolica de Chile
Study Sponsor  ICMJE Pontificia Universidad Catolica de Chile
Collaborators  ICMJE
  • Ministry of Health, Chile
  • Sinovac Biotech Co., Ltd
Investigators  ICMJE
Study Director: Katia Abarca, MD Pontificia Universidad Catolica de Chile
Study Director: Alexis M Kalergis, PhD Pontificia Universidad Catolica de Chile
Study Director: Susan M Bueno, PhD Pontificia Universidad Catolica de Chile
Study Director: Pablo A González, PhD Pontificia Universidad Catolica de Chile
PRS Account Pontificia Universidad Catolica de Chile
Verification Date February 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP